BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, December 26, 2025
Home » Authors » Sergio Held

Sergio Held

Articles

ARTICLES

Chile's med-tech distributors fear fallout and financial woes from public health debt crisis

May 13, 2016
By Sergio Held

Peru's pharma guild evaluates guidelines for biosimilars

May 9, 2016
By Sergio Held
BOGOTA, Colombia – Less than two months after Peru issued technical standards to register and re-register biosimilars, the new regulations are generating buzz in the country's biopharma space.
Read More

Argentina's Sinergium joins efforts to develop Zika virus vaccine

April 26, 2016
By Sergio Held
HONG KONG – Efforts are under way in Latin America to speed up the development of a vaccine for the Zika virus that has ran rampant in parts of the continent, most notably Brazil.
Read More

Mexican researchers achieve successful results with novel insulin microcapsule

April 25, 2016
By Sergio Held

No more talk: Novartis balks at Colombia price negotiations for Glivec

April 25, 2016
By Sergio Held
HONG KONG – Novartis AG pulled out of negotiations with the government of Colombia to determine a price for the leukemia drug Glivec (imatinib). Discussions had been initiated to prevent the issuance of a mandatory license. (See BioWorld Today, April 22, 2016.)
Read More

Novartis in price talks in Colombia to stave off compulsory license

April 22, 2016
By Sergio Held
BOGOTA, Colombia – Novartis AG is working against the clock in Colombia in a bid to prevent the Colombian government from issuing a mandatory license for the blockbuster cancer drug Glivec (imatinib).
Read More

Mexico seeks ban of cellphones in clinical setting

April 15, 2016
By Sergio Held

Nuvasive acquires its Brazilian distributor, gains public market access

March 15, 2016
By Sergio Held

Sientra reports losses, may shed Silimed as Brazilian manufacturer

March 11, 2016
By Sergio Held

Boston Scientific first med-tech company named in Brazilian cartel investigations

March 1, 2016
By Sergio Held
BOGOTA, Colombia — Boston Scientific do Brasil Ltda., the Brazilian subsidiary of the med-tech multinational, has emerged as the first company linked to an investigation into possible cartel activities in the largest market in Latin America.
Read More
View All Articles by Sergio Held

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing